AzTrials
AzTrials

Gastrointestinal CancerPhase 1NCT04195373

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

A Phase 1 study testing TMV-018 + 5-FC, TMV-018 + anti-PD-1 and TMV-018 + 5-FC + anti-PD-1 in people with Gastrointestinal Cancer, run by Themis Bioscience GmbH at 2 sites in Germany.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This study aims to determine the safety and tolerability of TMV-018 when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor in patients with gastrointestinal tumors. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Gastrointestinal Cancer
What is being tested?
TMV-018 + 5-FC, TMV-018 + anti-PD-1 and TMV-018 + 5-FC + anti-PD-1
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
2 sitesGermany
Study dates
23 Nov 2020to 23 Nov 2020
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed informed consent form must be obtained prior to any research procedures.
  • At least 18 years of age on the day of signing the informed consent.
  • Histologically confirmed diagnosis of advanced, metastatic tumors of the gastrointestinal tract (stage IV)
  • Before enrollment (i.e., at least 4 weeks before study treatment): Prior chemotherapy, targeted therapy, radiotherapy, to treat cancer or major surgery have to be stopped at least 4 weeks prior to enrolment.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and life expectancy ≥ 3 months as assessed during screening period.
  • All female participants of childbearing potential, defined as all woman physiologically capable of becoming pregnant, must have a negative pregnancy test at screening.
Show all 9Show fewer
  • Willingness not to become pregnant or to father a child during study participation by practicing reliable methods of contraception.
  • Patient must have exhausted all current standard therapy lines in the target cancer indications
  • Adequate organ function as determined by laboratory parameters.

Who cannot join

  • Patients who participated in other studies of anti-tumor therapy within 2 weeks before enrolment.
  • Patients with brain metastases.
  • Patients with poorly controlled hypertension, or cardiovascular and cerebrovascular diseases with clinical significance.
  • Patients with other serious organic diseases or mental disorders.
  • Patients with active infections, which cannot be controlled with drugs or have potential impact on treatment, or patients with concurrent opportunistic infections.
  • Patients exhibiting evidence of clinically significant immunosuppression such as primary or acquired immunodeficiency state
Show all 20Show fewer
  • Pregnancy (positive pregnancy test at screening or before end of study participation) or lactation at screening or planning to become pregnant before completion of study participation.
  • Males who have sex to conceive a child / who want to donate semen, during the study and up to 4 months after the last dose of TMV-018, 5-FC or pembrolizumab.
  • Males and female subjects of childbearing potential who are unwilling to use double barrier methods of effective contraception
  • Patients with an impaired renal function (creatinine clearance ≤ 40 mL/min).
  • Patients currently or recently (< 2 months) taking fluconazole, itraconazole, clotrimazole troches, itraconazole, amphotericin or other oral anti-fungal medications.
  • Patients with contraindications for treatment with flucytosine (5-FC)
  • Known hypersensitivity to 5-FU, known deficiency in dihydropyrimidine dehydrogenase (DPD)
  • Known hypersensitivity to pembrolizumab, its excipients, or other monoclonal antibody.
  • Severe immune-related adverse reactions from treatment with pembrolizumab, defined as any grade 4 toxicity or grade 3 toxicity requiring corticosteroid treatment (> 10 mg/day prednisone or equivalent) for greater than 12 weeks.
  • History or evidence of symptomatic autoimmune diseases.
  • Other medical condition or laboratory abnormality that in the judgment of the Investigator may increase the risk associated with study participation or may interfere with interpretation of study results.
  • History of severe systemic reaction or side-effect after a measles vaccination.
  • Subjects who continue to experience > grade 1 Common Terminology Criteria for Adverse Events (CTCAE) toxicity due to cancer therapy within 4 weeks prior to enrollment will not be eligible.
  • Use of anti-cancer treatments within 4 weeks of TMV-018 treatment start.

Trial locations and contacts

2 sites in 1 country.

Germany2 sites

  • University Hospital Bonn

    Bonn

  • University Hospital Tübingen

    Tübingen

Other trials in Germany

About this study

Official title: A Phase I Open-label, Safety Study of Intra-tumoral Application of TMV-018 in Combination With 5-FC or Anti-PD-1 Therapy in Patients With Tumors of the Gastrointestinal Tract

This study aims to determine the safety and tolerability of TMV-018 when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor in patients with gastrointestinal tumors. Furthermore, the maximum tolerated dose (MTD) and recommended Phase II dose of TMV-018 shall be determined.

Read the detailed description

This is an open-label, multicenter, dose-escalation phase I trial that aims to determine the safety and tolerability of TMV-018, an oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase", when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor up to day 72 in patients with colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer. Furthermore, the maximum tolerated dose (MTD) and recommended Phase II dose of TMV-018 shall be determined.

At least 15 patients will be enrolled. Patients will be randomized to different treatment groups: all patients will receive intra-tumoral TMV-018 on four visits and additionally 5-FC and/or anti-PD-1 treatment. All adverse events will be documented and analyzed for the primary safety endpoint. Blood and tumor samples will be collected up to day 72 to determine the safety, tolerability and immunogenicity of the treatment. The patients will be followed-up for another two years to determine long-term safety.

Being tested
TMV-018 + 5-FC, TMV-018 + anti-PD-1, TMV-018 + 5-FC + anti-PD-1
Keywords
Colorectal cancer, Esophageal cancer, Gastric cancer, TMV-018, anti-PD-1, 5-FC, oncolytic virus
Medical subject headings
Gastrointestinal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TMV-018 + 5-FCBiological

    TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.

    5-FC: 150 mg/kg/day for 2 days during each treatment.

  • TMV-018 + anti-PD-1Biological

    TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.

    Anti-PD-1 inhibitor dose according to its SMPC.

  • TMV-018 + 5-FC + anti-PD-1Biological

    TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme "super cytosine deaminase"; 1E+06 TCID50 to 1E+08 TCID50 per dose.

    5-FC: 150 mg/kg/day for 2 days during each treatment cycle.

    Anti-PD-1 Inhibitor: dose according to its SMPC.

Study groups in NCT04195373
Study groupRoleWhat they receive
TMV-018 + 5-FCExperimentalPatients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC.
Receives: Biological: TMV-018 + 5-FC
TMV-018 + anti-PD-1 inhibitorExperimentalPatients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with an anti-PD-1 Inhibitor.
Receives: Biological: TMV-018 + anti-PD-1
TMV-018 + 5-FC + anti-PD-1 inhibitorExperimentalPatients will receive intra-tumoral TMV-018 on days 0, 14, 28 and 42, and will be additionally treated with the prodrug 5-FC and an anti-PD-1 Inhibitor.
Receives: Biological: TMV-018 + 5-FC + anti-PD-1

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Frequency of Adverse Events

    Incidence of solicited and unsolicited adverse events from enrollment until end of study.

    Measured: 4 years

  2. Determine MTD and dose for phase II

    Determine the maximum tolerated dose (MTD) and recommended Phase II dose of TMV-018

    Measured: 1.5 years

Secondary outcomes (4)

  1. Viral replication

    Assess viral replication at injected tumor sites, viremia (distribution of i.t. applied TMV-018 into the blood stream), and shedding as well as possible persistence phenomena of TMV-018

    Measured: 2 years

  2. Viral distribution

    Assess viremia (distribution of i.t. applied TMV-018 into the blood stream) and shedding as well as possible persistence phenomena of TMV-018

    Measured: 2 years

  3. Efficacy of therapy assessed by RECIST 1.1

    Assess the therapeutic efficacy of TMV-018 with 5-FC or anti-PD-1 therapy by radiologic assessment (RECIST 1.1, time to progression).

    Measured: 4 years

  4. Efficacy of therapy assessed by changes in tumor marker level

    Assess the therapeutic efficacy of TMV-018 with 5-FC or anti-PD-1 therapy by changes in tumor marker level.

    Measured: 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Dec 2019
  2. Study start23 Nov 2020
  3. Primary completion23 Nov 2020
  4. Study completion23 Nov 2020

Why it stopped: Study not started, no subjects recruited.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04195373
Sponsor's protocol ID
TMV-018-101
Status last verified
Nov 2020
First submitted
5 Dec 2019
Last updated
25 Nov 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing TMV-018 + 5-FC, TMV-018 + anti-PD-1 and TMV-018 + 5-FC + anti-PD-1 in people with Gastrointestinal Cancer, run by Themis Bioscience GmbH at 2 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 25 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Frequency of Adverse Events (time frame: 4 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04195373.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Nov 2020; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in